Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
AssigneeEli Lilly and Company
InventorsTamer Coskun, Wolfgang Glaesner
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.
Claims23
1-15. (canceled)
A method of treating obesity comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound is an FGF-21 analog selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO:
- 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:
- 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO:
- 11), Cys26-Cys122-Ala167-FGF-21 (SEQ ID NO:
- 12), and Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO:
- 13).
A method of lowering body weight comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound is an FGF-21 analog selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO:
- 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO:
- 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO:
- 11), Cys26-Cys122-Ala167-FGF-21 (SEQ ID NO:
- 12), and Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO:
- 13).
Dependencies are inferred from the claim text.